The UK gene and cell therapy company, Oxford BioMedica PLC, has transformed its business over the past year, becoming debt-free, signing new collaborations with big pharma, and is now progressing a pipeline of preclinical product candidates using its lentivirus gene-delivery platform. Its latest revenue-earner is a $200m tie-up with Juno Therapeutics Inc..
Juno Therapeutics, a Bristol-Myers Squibb Co. subsidiary, has received a non-exclusive license to Oxford Biomedica’s LentiVector platform to use in its CAR-T and TCR-T programs in oncology and other indications
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?